Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abt-072. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-072 SCHEMBL1530784 | 1.00 | CRBN (0.62) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL2482783 | 0.99 | CRBN (0.61) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL2482781 | 0.99 | CRBN (0.61) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL479128 | 0.99 | CRBN (0.63) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL29376933 | 0.99 | CRBN (0.63) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL479219 | 0.99 | CRBN (0.63) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL1530682 | 0.99 | CRBN (0.63) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL1530713 | 0.98 | CRBN (0.62) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL1530716 | 0.98 | CRBN (0.62) | CRBNCYP3A4TRPV1TNFRSF1A | |
| Abt-072 SCHEMBL1530708 | 0.98 | CRBN (0.62) | CRBNCYP3A4TRPV1TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8986740-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20120189580-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | claimed |
| EP-2377854-A1 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | claimed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | claimed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8986740-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2725015-A1 | Uracil or thymine derivative for treating hepatitis c | AbbVie Bahamas Ltd. (BS) | 2014-04-30 | — | — | EP | disclosed |
| US-8415351-B2 | Anti-infective agents and uses thereof | ABBOTT LABORATORIES (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2548873-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120189580-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2377854-A1 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2203430-B1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LAB (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2203430-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885TRPV1 3535/4885 |
| US-20120189580-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885TRPV1 3535/4885 |
| US-20120213733-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885TRPV1 3535/4885 |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CRBN 3902/4885CYP3A4 1675/4885TRPV1 3535/4885 |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | MPO, ELANE, LPO | CRBN 3874/4885CYP3A4 1348/4885TRPV1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.